The Latest Breaking News from Medicare

The Medicare rebate for getting an intra-uterine device (IUD) inserted has been raised but doctors say it still does not come close to covering the cost of the procedure.

Cognitive behavioural therapy (CBT) is one of the most popular forms of talking therapy. It is the treatment of choice for depression and anxiety and is a staple of public healthcare systems, such as the NHS and the Australian Medicare system. CBT’s understanding of mental illness and therapeutic techniques is…

With prospects dim for the U.S. to adopt a single-payer “Medicare for All” program, health care reform advocates turned instead to an insurance plan designed by the government that could compete with private insurance plans sold on the health care exchanges. The idea behind this “public option” is that it…

WASHINGTON — If Republicans take one or both chambers of Congress in November, don’t be surprised if shoring up Social Security’s finances becomes an area of bipartisan focus.

Veterans of previous bipartisan working groups in the Senate have begun talking about the need for fixes to counter future shortfalls.

Monoclonal antibodies have emerged as a powerful tool for reducing hospitalization and death from COVID-19, but recently published studies suggests that the lab-created proteins are going to those who need them less — patients with the fewest chronic conditions — while usage in hospital outpatient clinics has followed a persistent…

The drug industry, patient advocates and congressional Republicans have all attacked federal officials’ decision to decline routine Medicare coverage for a controversial Alzheimer’s drug. They’ve gone as far as to accuse them of tacit racism, ageism and discrimination against the disabled — and hinted at a lawsuit — over the…

WASHINGTON — Advocates on both sides of a debate over dramatically restricting Medicare’s coverage of an expensive and controversial Alzheimer’s treatment are waging competing campaigns to influence a final decision in April.

Competing campaigns look to influence the debate over dramatically restricting coverage of a controversial treatment drug Aduhelm.